Displaying 1961 - 1980 of 2301
FTC Provides Senate Testimony on Anticompetitive Patent Settlements in the U.S. Pharmaceutical Industry
Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of
A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.
There is a related federal proceeding and two related administrative proceedings:
FTC Provides Senate Testimony on Sports Programming and Cable Distribution
FTC Charges Real Estate Groups with Anticompetitive Conduct in Limiting Consumers' Choice in Real Estate Services
FTC Provides House Testimony on Competition Issues in the Contact Lens Industry
FTC Finds Rambus Unlawfully Obtained Monopoly Power
FTC Requires Asset Divestitures Before Allowing Boston Scientifics $27 Billion Acquisition of Guidant Corporation
Texas Doctors' IPA Agrees to Settle Price Fixing Charges
Competition Policy and the Real Estate Industry: A Public Workshop hosted by the Federal Trade Commission and Department of Justice
FTC Resolves Aloha Petroleum Litigation
Dual Consent Orders Resolve Competitive Concerns About Chevrons $18 Billion Purchase of Unocal, FTCs 2003 Complaint Against Unocal
Northwest New Mexico Physicians Agree to Settle FTC Charges That They Fixed Prices
FTC Halts Physician Price-Fixing in Cincinnati Area
Displaying 1961 - 1980 of 2301